AN2 Therapeutics
NASDAQ: ANTXMenlo Park, US · Founded 2019 · Incorporated in Delaware · 38 employees on LinkedIn · Public · 6 known investors
Find your way into AN2 Therapeutics
87 people in our graph share verified history with the AN2 Therapeutics team — schools, employers, funds. One of them is your warm intro.
AN2 Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule drugs from its boron chemistry platform, with a pipeline spanning hematologic diseases, infectious diseases, oncology, and bone disorders. It targets diseases with significant unmet medical needs.
Also known as AN2
Founders & leadership
AN2 Therapeutics was founded in 2019 by Joseph S. Zakrzewski, Eric Easom, George H. Talbot, and Michael R.K. (Dickon) Alley.
Board
Investors · 6
Funding
SEC filings, press & company announcements$40M disclosed across 1 of 2 rounds · 2026
- Undisclosed amountprivate placementMar 2026Source ↗
▶$40MraisedMar 2026 · 16 investors · PharmaceuticalsRule 506(b)
- Margaret FitzPatrickDirector
- Patricia MartinDirector
- Melvin SpigelmanDirector
- Gilbert Lynn MarksDirector
- Stephanie WongDirector
- Joseph S. ZakrzewskiDirector
- Joshua EizenExecutive Officer
- Kabeer AzizDirector
- Rob ReadnourDirector
- Sanjay ChandaExecutive Officer
- Lucy DayExecutive Officer
- Eric EasomExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $40M
- Sales commissions
- $2.4M
- Placement agents
- Leerink Partners LLC
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026AN2 Therapeutics is a biopharmaceutical company based in Menlo Park, California, developing novel therapies from a boron chemistry platform. The company describes a pipeline of boron-based compounds intended to address hematology, infectious disease and oncology indications, with a stated aim of delivering drugs for critical unmet medical needs and improved health outcomes.
Disclosed pipeline programs include epetraborole and AN2-502998, an oral candidate. The company maintains clinical trial, presentation and publication resources alongside an expanded access policy.
Business model
The company develops proprietary small-molecule drug candidates from its boron chemistry platform and lists a business development contact for partnering, alongside internal pipeline programs such as epetraborole and AN2-502998.
▸Full profile — market position, technology, go-to-market, geography
Market position
AN2 Therapeutics positions its boron-based compounds as potential best-in-class therapeutics across hematology, infectious disease and oncology.
Technology
The company's drug discovery is built on a boron chemistry platform, which it describes as suited to delivering novel, potentially first-in-class targets and best-in-class boron-based compounds.
Go-to-market
Patients with hematologic diseases, infectious diseases and cancers characterized by significant unmet medical need.
Geography
Headquarters and offices at 1300 El Camino Real, Suite 100, Menlo Park, California 94025, United States.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Competitors · 2
by search overlap
Companies competing with AN2 Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
AN2 Therapeutics posts Q2 2026 loss, builds cash | ANTX Quarterly Report (10-Q)stocktitan.net · Aug 2026
AN2 Therapeutics (ANTX) deepens Phase 2 pipeline while Q2 2026 loss widensstocktitan.net · Aug 2026▸Research sources · 1
primary sources listed
- AN2 Therapeuticsan2therapeutics.com · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does AN2 Therapeutics do?
- AN2 Therapeutics develops boron-based small-molecule therapies for hematology, infectious disease and oncology.
- Who founded AN2 Therapeutics?
- AN2 Therapeutics was founded by Joseph S. Zakrzewski, Eric Easom, George H. Talbot, Michael R.K. (Dickon) Alley in 2019.
- Who are AN2 Therapeutics's investors?
- AN2 Therapeutics's investors include Adjuvant Capital, BioRock Ventures, Flucas Ventures, Mountain Group Capital, RA Capital, Hatteras Venture Partners.
- How much funding has AN2 Therapeutics raised?
- AN2 Therapeutics has disclosed $40M raised across 1 of its 2 known rounds.
- Is AN2 Therapeutics publicly traded?
- Yes — AN2 Therapeutics trades on NASDAQ under the ticker ANTX.
- Where is AN2 Therapeutics headquartered?
- AN2 Therapeutics is headquartered in Menlo Park, US.